Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 500

1.

Allogeneic Hematopoietic Cell Transplantation Outcomes in Patients Carrying Isocitrate Dehydrogenase Mutations.

Salhotra A, Afkhami M, Yang D, Mokhtari S, Telatar M, Gu D, Pillai RK, Weisenburger DD, Murata-Collins J, Weigel D, Aoun P, Aldoss I, Al Malki MM, Khaled S, Mei M, Ali H, Aribi A, Budde E, Sandhu K, O'Donnell M, Snyder D, Pullarkat V, Forman SJ, Marcucci G, Nakamura R, Stein A.

Clin Lymphoma Myeloma Leuk. 2019 Apr 26. pii: S2152-2650(18)31738-5. doi: 10.1016/j.clml.2019.04.007. [Epub ahead of print]

PMID:
31155409
2.

CD123 CAR T cells for the treatment of myelodysplastic syndrome.

Stevens BM, Zhang W, Pollyea DA, Winters A, Gutman J, Smith C, Budde E, Forman SJ, Jordan CT, Purev E.

Exp Hematol. 2019 May 25. pii: S0301-472X(19)30319-4. doi: 10.1016/j.exphem.2019.05.002. [Epub ahead of print]

PMID:
31136781
3.

Favorable outcomes for allogeneic hematopoietic cell transplantation in elderly patients with NPM1-mutated and FLT3-ITD-negative acute myeloid leukemia.

Aldoss I, Nakamura R, Yang D, Salhotra A, Stein AS, Pullarkat V, Forman SJ, Marcucci G.

Bone Marrow Transplant. 2019 May 14. doi: 10.1038/s41409-019-0553-x. [Epub ahead of print] No abstract available.

PMID:
31089274
4.

Impact of Sarcopenia on Adverse Outcomes After Allogeneic Hematopoietic Cell Transplantation.

Armenian SH, Xiao M, Berano Teh J, Lee B, Chang HA, Mascarenhas K, Lee S, Iukuridze A, Xie JJ, Scott JM, Jones LW, Lennie Wong F, Forman SJ, Nakamura R.

J Natl Cancer Inst. 2019 Feb 14. pii: djy231. doi: 10.1093/jnci/djy231. [Epub ahead of print]

PMID:
30951603
5.

IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype.

Alizadeh D, Wong RA, Yang X, Wang D, Pecoraro JR, Kuo CF, Aguilar B, Qi Y, Ann DK, Starr R, Urak R, Wang X, Forman SJ, Brown CE.

Cancer Immunol Res. 2019 May;7(5):759-772. doi: 10.1158/2326-6066.CIR-18-0466. Epub 2019 Mar 19.

PMID:
30890531
6.

Late mortality in blood or marrow transplant survivors with venous thromboembolism: report from the Blood or Marrow Transplant Survivor Study.

Gangaraju R, Chen Y, Hageman L, Wu J, Francisco L, Kung M, Ness E, Parman M, Weisdorf DJ, Forman SJ, Arora M, Armenian SH, Bhatia S.

Br J Haematol. 2019 Mar 18. doi: 10.1111/bjh.15866. [Epub ahead of print] No abstract available.

PMID:
30883690
7.

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function.

Wang D, Starr R, Alizadeh D, Yang X, Forman SJ, Brown CE.

J Vis Exp. 2019 Feb 27;(144). doi: 10.3791/59275.

PMID:
30882787
8.

Acute Lymphoblastic Leukemia in the Older Adult.

Aldoss I, Forman SJ, Pullarkat V.

J Oncol Pract. 2019 Feb;15(2):67-75. doi: 10.1200/JOP.18.00271.

PMID:
30763199
9.

Post-Allogeneic Hematopoietic Stem Cell Transplantation Eculizumab as Prophylaxis Against Hemolysis and Thrombosis for Patients with Hematologic Disorders Associated with Paroxysmal Nocturnal Hemoglobinuria Clones.

Mei M, Gupta R, O'Donnell M, Al Malki MM, Aldoss I, Ali H, Farol L, Snyder D, Forman SJ, Nakamura R, Khaled S.

Biol Blood Marrow Transplant. 2019 May;25(5):e183-e185. doi: 10.1016/j.bbmt.2019.01.025. Epub 2019 Jan 29.

PMID:
30708188
10.

Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis.

Al-Mansour Z, Li H, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS, Smith SM, Marcellus DC, Barton KP, Mills GM, LeBlanc M, Rimsza LM, Forman SJ, Leonard JP, Fisher RI, Friedberg JW, Stiff PJ.

Leuk Lymphoma. 2019 Jan 10:1-8. doi: 10.1080/10428194.2018.1563691. [Epub ahead of print]

PMID:
30628511
11.

The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML.

Nguyen LXT, Troadec E, Kalvala A, Kumar B, Hoang DH, Viola D, Zhang B, Nguyen DQ, Aldoss I, Ghoda L, Budde E, Pichiorri F, Rosen S, Forman SJ, Marcucci G, Pullarkat V.

J Cell Physiol. 2019 Aug;234(8):14040-14049. doi: 10.1002/jcp.28091. Epub 2019 Jan 8.

PMID:
30623427
12.

MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen.

Ali H, Aldoss I, Yang D, Mokhtari S, Khaled S, Aribi A, Afkhami M, Al Malki MM, Cao T, Mei M, O'Donnell M, Salhotra A, Pullarkat V, Yang L, Stein AS, Marcucci G, Forman SJ, Nakamura R, Pillai R, Snyder D.

Blood Adv. 2019 Jan 8;3(1):83-95. doi: 10.1182/bloodadvances.2018026658.

13.

Effective Targeting of TAG72+ Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells.

Murad JP, Kozlowska AK, Lee HJ, Ramamurthy M, Chang WC, Yazaki P, Colcher D, Shively J, Cristea M, Forman SJ, Priceman SJ.

Front Immunol. 2018 Nov 19;9:2268. doi: 10.3389/fimmu.2018.02268. eCollection 2018.

14.

Adults with Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia: Considerations for Allogeneic Hematopoietic Cell Transplantation in First Complete Remission.

Aldoss I, Kamal MO, Forman SJ, Pullarkat V.

Biol Blood Marrow Transplant. 2019 Feb;25(2):e41-e45. doi: 10.1016/j.bbmt.2018.09.041. Epub 2018 Oct 5.

PMID:
30292743
15.

Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis.

Salhotra A, Mei M, Stiller T, Mokhtari S, Herrera AF, Chen R, Popplewell L, Zain J, Ali H, Sandhu K, Budde E, Nademanee A, Forman SJ, Nakamura R.

Biol Blood Marrow Transplant. 2019 Feb;25(2):287-292. doi: 10.1016/j.bbmt.2018.09.009. Epub 2018 Sep 15.

PMID:
30227232
16.

Assessment of Late Mortality Risk After Allogeneic Blood or Marrow Transplantation Performed in Childhood.

Holmqvist AS, Chen Y, Wu J, Battles K, Bhatia R, Francisco L, Hageman L, Kung M, Ness E, Parman M, Salzman D, Wadhwa A, Winther JF, Rosenthal J, Forman SJ, Weisdorf DJ, Armenian SH, Arora M, Bhatia S.

JAMA Oncol. 2018 Dec 1;4(12):e182453. doi: 10.1001/jamaoncol.2018.2453. Epub 2018 Dec 13.

PMID:
30054602
17.

Prediction of cardiovascular disease among hematopoietic cell transplantation survivors.

Armenian SH, Yang D, Teh JB, Atencio LC, Gonzales A, Wong FL, Leisenring WM, Forman SJ, Nakamura R, Chow EJ.

Blood Adv. 2018 Jul 24;2(14):1756-1764. doi: 10.1182/bloodadvances.2018019117.

18.

Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma.

Aldoss I, Capelletti M, Park J, Pistofidis RS, Pillai R, Stiller T, Sanchez JF, Forman SJ, Ghobrial IM, Krishnan A.

Leukemia. 2019 Jan;33(1):266-270. doi: 10.1038/s41375-018-0213-y. Epub 2018 Jul 19.

PMID:
30026571
19.

Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation.

Chen RW, Palmer JM, Tomassetti S, Popplewell LL, Alluin J, Chomchan P, Nademanee AP, Siddiqi T, Tsai NC, Chen L, Zuo F, Abary R, Cai JL, Herrera AF, Rossi JJ, Rosen ST, Forman SJ, Kwak LW, Holmberg LA.

J Hematol Oncol. 2018 Jun 28;11(1):87. doi: 10.1186/s13045-018-0631-3.

20.

Late mortality after allogeneic blood or marrow transplantation in childhood for leukemia: a report from the Blood or Marrow Transplant Survivor Study-2.

Holmqvist AS, Chen Y, Wu J, Kung M, Ness E, Parman M, Francisco L, Hageman L, Battles K, Bhatia R, Salzman D, Winther JF, Rosenthal J, Forman SJ, Weisdorf DJ, Armenian SH, Arora M, Bhatia S.

Leukemia. 2018 Dec;32(12):2706-2709. doi: 10.1038/s41375-018-0171-4. Epub 2018 Jun 26. No abstract available.

PMID:
29946190
21.

Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients.

Aldoss I, Stiller T, Tsai NC, Song JY, Cao T, Bandara NA, Salhotra A, Khaled S, Aribi A, Al Malki MM, Mei M, Ali H, Spielberger R, O'Donnell M, Snyder D, Slavin T, Nakamura R, Stein AS, Forman SJ, Marcucci G, Pullarkat V.

Haematologica. 2018 Oct;103(10):1662-1668. doi: 10.3324/haematol.2018.193599. Epub 2018 Jun 14.

22.

Regulation of miR-34b/c-targeted gene expression program by SUMOylation.

Li YJ, Du L, Aldana-Masangkay G, Wang X, Urak R, Forman SJ, Rosen ST, Chen Y.

Nucleic Acids Res. 2018 Aug 21;46(14):7108-7123. doi: 10.1093/nar/gky484.

23.

Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity.

Wang D, Aguilar B, Starr R, Alizadeh D, Brito A, Sarkissian A, Ostberg JR, Forman SJ, Brown CE.

JCI Insight. 2018 May 17;3(10). pii: 99048. doi: 10.1172/jci.insight.99048. eCollection 2018 May 17.

24.

Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.

Al Malki MM, Nathwani N, Yang D, Armenian S, Dadwal S, Salman J, Mokhtari S, Cao T, Sandhu K, Rouse M, Mei M, Ali H, Parker P, Alvarnas J, Smith E, Donnell MO, Marcucci G, Snyder D, Nademanee A, Forman SJ, Stein A, Nakamura R.

Biol Blood Marrow Transplant. 2018 Sep;24(9):1828-1835. doi: 10.1016/j.bbmt.2018.04.029. Epub 2018 May 9.

PMID:
29753158
25.

PET of Adoptively Transferred Chimeric Antigen Receptor T Cells with 89Zr-Oxine.

Weist MR, Starr R, Aguilar B, Chea J, Miles JK, Poku E, Gerdts E, Yang X, Priceman SJ, Forman SJ, Colcher D, Brown CE, Shively JE.

J Nucl Med. 2018 Oct;59(10):1531-1537. doi: 10.2967/jnumed.117.206714. Epub 2018 May 4.

26.

A Future for Autologous Hematopoietic Stem Cell Transplantation in Type 1 Diabetes.

van Megen KM, van 't Wout ET, Forman SJ, Roep BO.

Front Immunol. 2018 Apr 6;9:690. doi: 10.3389/fimmu.2018.00690. eCollection 2018. No abstract available.

27.

Late mortality after autologous blood or marrow transplantation in childhood: a Blood or Marrow Transplant Survivor Study-2 report.

Holmqvist AS, Chen Y, Wu J, Battles K, Bhatia R, Francisco L, Hageman L, Kung M, Ness E, Parman M, Salzman D, Winther JF, Rosenthal J, Forman SJ, Weisdorf DJ, Arora M, Armenian SH, Bhatia S.

Blood. 2018 Jun 14;131(24):2720-2729. doi: 10.1182/blood-2018-02-831156. Epub 2018 Apr 16.

28.

Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.

Aldoss I, Yang D, Aribi A, Ali H, Sandhu K, Al Malki MM, Mei M, Salhotra A, Khaled S, Nakamura R, Snyder D, O'Donnell M, Stein AS, Forman SJ, Marcucci G, Pullarkat V.

Haematologica. 2018 Sep;103(9):e404-e407. doi: 10.3324/haematol.2018.188094. Epub 2018 Mar 15. No abstract available.

29.

Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia.

Zhang B, Nguyen LXT, Li L, Zhao D, Kumar B, Wu H, Lin A, Pellicano F, Hopcroft L, Su YL, Copland M, Holyoake TL, Kuo CJ, Bhatia R, Snyder DS, Ali H, Stein AS, Brewer C, Wang H, McDonald T, Swiderski P, Troadec E, Chen CC, Dorrance A, Pullarkat V, Yuan YC, Perrotti D, Carlesso N, Forman SJ, Kortylewski M, Kuo YH, Marcucci G.

Nat Med. 2018 May;24(4):450-462. doi: 10.1038/nm.4499. Epub 2018 Mar 5.

30.

Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer.

Priceman SJ, Gerdts EA, Tilakawardane D, Kennewick KT, Murad JP, Park AK, Jeang B, Yamaguchi Y, Yang X, Urak R, Weng L, Chang WC, Wright S, Pal S, Reiter RE, Wu AM, Brown CE, Forman SJ.

Oncoimmunology. 2017 Oct 16;7(2):e1380764. doi: 10.1080/2162402X.2017.1380764. eCollection 2018.

31.

Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703).

Smith EP, Li H, Friedberg JW, Constine LS, Rimsza LM, Cook JR, Laport GG, Popplewell LL, Holmberg LA, Smith SM, LeBlanc M, Forman SJ, Fisher RI, Stiff PJ.

Biol Blood Marrow Transplant. 2018 Apr;24(4):700-707. doi: 10.1016/j.bbmt.2017.12.798. Epub 2017 Dec 28.

32.

Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma.

Herrera AF, Palmer J, Martin P, Armenian S, Tsai NC, Kennedy N, Sahebi F, Cao T, Budde LE, Mei M, Siddiqi T, Popplewell L, Rosen ST, Kwak LW, Nademanee A, Forman SJ, Chen R.

Ann Oncol. 2018 Mar 1;29(3):724-730. doi: 10.1093/annonc/mdx791.

33.

Cognitive Functioning After Hematopoietic Cell Transplantation for Hematologic Malignancy: Results From a Prospective Longitudinal Study.

Sharafeldin N, Bosworth A, Patel SK, Chen Y, Morse E, Mather M, Sun C, Francisco L, Forman SJ, Wong FL, Bhatia S.

J Clin Oncol. 2018 Feb 10;36(5):463-475. doi: 10.1200/JCO.2017.74.2270. Epub 2017 Dec 18.

PMID:
29252122
34.

Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma.

Krishnan A, Kapoor P, Palmer JM, Tsai NC, Kumar S, Lonial S, Htut M, Karanes C, Nathwani N, Rosenzweig M, Sahebi F, Somlo G, Duarte L, Sanchez JF, Auclair D, Forman SJ, Berdeja JG.

Leukemia. 2017 Dec 18. doi: 10.1038/leu.2017.352. [Epub ahead of print]

35.

Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Gray Zone Lymphoma: A US Multicenter Collaborative Study.

Kharfan-Dabaja MA, Raj R, Nikolaenko L, Ahmed S, Reddy N, Nathan S, Cherry M, El-Jurdi N, Obiozor C, Fenske TS, Song J, Muzzafar T, Ayala E, Savani B, Khawandanah M, Caimi PF, Hamadani M, Forman SJ, Hussaini M, de Lima M, Olteanu H, Shah B, Chavez JC, Al Malki M, Kumar A, Ganguly S.

Biol Blood Marrow Transplant. 2018 Mar;24(3):486-493. doi: 10.1016/j.bbmt.2017.11.033. Epub 2017 Dec 7.

36.

Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma.

Herrera AF, Rodig SJ, Song JY, Kim Y, Griffin GK, Yang D, Nikolaenko L, Mei M, Bedell V, Dal Cin P, Pak C, Alyea EP, Budde LE, Chen R, Chen YB, Chan WC, Cutler CS, Ho VT, Koreth J, Krishnan A, Murata-Collins JL, Nikiforow S, Palmer J, Pihan GA, Pillai R, Popplewell L, Rosen ST, Siddiqi T, Sohani AR, Zain J, Kwak LW, Weisenburger DD, Weinstock DM, Soiffer RJ, Antin JH, Forman SJ, Nademanee AP, Armand P.

Biol Blood Marrow Transplant. 2018 Mar;24(3):514-520. doi: 10.1016/j.bbmt.2017.11.023. Epub 2017 Nov 28.

37.

Prevalence of anthracycline-related cardiac dysfunction in long-term survivors of adult-onset lymphoma.

Armenian SH, Mertens L, Slorach C, Venkataraman K, Mascarenhas K, Nathwani N, Wong FL, Forman SJ, Bhatia S.

Cancer. 2018 Feb 15;124(4):850-857. doi: 10.1002/cncr.31110. Epub 2017 Nov 7.

38.

Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma.

Brown CE, Aguilar B, Starr R, Yang X, Chang WC, Weng L, Chang B, Sarkissian A, Brito A, Sanchez JF, Ostberg JR, D'Apuzzo M, Badie B, Barish ME, Forman SJ.

Mol Ther. 2018 Jan 3;26(1):31-44. doi: 10.1016/j.ymthe.2017.10.002. Epub 2017 Oct 5.

39.

Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2+ Breast Cancer Metastasis to the Brain.

Priceman SJ, Tilakawardane D, Jeang B, Aguilar B, Murad JP, Park AK, Chang WC, Ostberg JR, Neman J, Jandial R, Portnow J, Forman SJ, Brown CE.

Clin Cancer Res. 2018 Jan 1;24(1):95-105. doi: 10.1158/1078-0432.CCR-17-2041. Epub 2017 Oct 23.

40.

Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma.

Wang X, Walter M, Urak R, Weng L, Huynh C, Lim L, Wong CW, Chang WC, Thomas SH, Sanchez JF, Yang L, Brown CE, Pichiorri F, Htut M, Krishnan AY, Forman SJ.

Clin Cancer Res. 2018 Jan 1;24(1):106-119. doi: 10.1158/1078-0432.CCR-17-0344. Epub 2017 Oct 23.

41.

US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL.

Ravandi F, Othus M, O'Brien SM, Forman SJ, Ha CS, Wong JYC, Tallman MS, Paietta E, Racevskis J, Uy GL, Horowitz M, Takebe N, Little R, Borate U, Kebriaei P, Kingsbury L, Kantarjian HM, Radich JP, Erba HP, Appelbaum FR.

Blood Adv. 2016 Dec 27;1(3):250-259. doi: 10.1182/bloodadvances.2016001495.

42.

Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study.

Kharfan-Dabaja MA, Al Malki MM, Deotare U, Raj RV, El-Jurdi N, Majhail N, Cherry MA, Bashir Q, Darrah J, Nishihori T, Sibai H, Hamadani M, de Lima M, Gerds AT, Selby G, Qazilbash MH, Forman SJ, Ayala E, Lipton JH, Hari PN, Muzzafar T, Zhang L, Olteanu H, Perkins J, Sokol L, Kumar A, Ahmed S.

Br J Haematol. 2017 Dec;179(5):781-789. doi: 10.1111/bjh.14954. Epub 2017 Oct 4.

PMID:
28980314
43.

Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of TP53 mutational status.

Aldoss I, Pham A, Li SM, Gendzekhadze K, Afkhami M, Telatar M, Hong H, Padeganeh A, Bedell V, Cao T, Khaled SK, Malki MMA, Salhotra A, Ali H, Aribi A, Palmer J, Aoun P, Spielberger R, Stein AS, Snyder D, O'Donnell MR, Murata-Collins J, Senitzer D, Weisenburger D, Forman SJ, Pullarkat V, Marcucci G, Pillai R, Nakamura R.

Haematologica. 2017 Dec;102(12):2030-2038. doi: 10.3324/haematol.2017.172544. Epub 2017 Sep 29.

44.

How I treat patients with HIV-related hematological malignancies using hematopoietic cell transplantation.

Alvarnas JC, Zaia JA, Forman SJ.

Blood. 2017 Nov 2;130(18):1976-1984. doi: 10.1182/blood-2017-04-551606. Epub 2017 Sep 7. Review.

45.

Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab.

Mei MG, Cao TM, Chen L, Song JY, Siddiqi T, Cai JL, Farol LT, Al Malki MM, Salhotra A, Aldoss I, Palmer J, Herrera AF, Zain J, Popplewell LL, Chen RW, Rosen ST, Forman SJ, Kwak L, Nademanee AP, Budde LE.

Biol Blood Marrow Transplant. 2017 Nov;23(11):1861-1869. doi: 10.1016/j.bbmt.2017.07.006. Epub 2017 Jul 18.

46.

Stabilization of the c-Myc Protein by CAMKIIγ Promotes T Cell Lymphoma.

Gu Y, Zhang J, Ma X, Kim BW, Wang H, Li J, Pan Y, Xu Y, Ding L, Yang L, Guo C, Wu X, Wu J, Wu K, Gan X, Li G, Li L, Forman SJ, Chan WC, Xu R, Huang W.

Cancer Cell. 2017 Jul 10;32(1):115-128.e7. doi: 10.1016/j.ccell.2017.06.001.

47.

Antileukemic activity and cellular effects of the antimalarial agent artesunate in acute myeloid leukemia.

Kumar B, Kalvala A, Chu S, Rosen S, Forman SJ, Marcucci G, Chen CC, Pullarkat V.

Leuk Res. 2017 Aug;59:124-135. doi: 10.1016/j.leukres.2017.05.007. Epub 2017 May 10.

PMID:
28646646
48.

Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Chemotherapy in Mantle Cell Lymphoma Patients Is Associated with Higher Rates of Hematopoietic Progenitor Cell Mobilization Failure despite Plerixafor Rescue.

Salhotra A, Shan Y, Tsai NC, Sanchez JF, Aldoss I, Ali H, Paris T, Spielberger R, Cao TM, Nademanee A, Forman SJ, Chen R.

Biol Blood Marrow Transplant. 2017 Aug;23(8):1264-1268. doi: 10.1016/j.bbmt.2017.04.011. Epub 2017 Apr 18.

49.

Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy.

Urak R, Walter M, Lim L, Wong CW, Budde LE, Thomas S, Forman SJ, Wang X.

J Immunother Cancer. 2017 Mar 21;5:26. doi: 10.1186/s40425-017-0227-4. eCollection 2017.

50.

Phase II Study of Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BCNU, Etoposide, Cytarabine, and Melphalan for Non-Hodgkin Lymphoma: The Role of Histology.

Krishnan AY, Palmer J, Nademanee AP, Chen R, Popplewell LL, Tsai NC, Sanchez JF, Simpson J, Spielberger R, Yamauchi D, Forman SJ.

Biol Blood Marrow Transplant. 2017 Jun;23(6):922-929. doi: 10.1016/j.bbmt.2017.03.004. Epub 2017 Mar 4.

Supplemental Content

Loading ...
Support Center